Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 54: 218-220, 2008; 10.1373/clinchem.2007.096412
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Neale, S.
Right arrow Articles by Ayling, R. M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neale, S.
Right arrow Articles by Ayling, R. M
(Clinical Chemistry. 2008;54:218-220.)
© 2008 American Association for Clinical Chemistry, Inc.

Letters to the Editor

Drug Monitoring and Toxicology (DMT)

Sarah Neale1, Anne Brown2, Jinny Jeffery1 and Ruth M Ayling1,a

1 Departments of Clinical Biochemistry, Derriford Hospital Plymouth and 2 Southmead Hospital Bristol

aAddress correspondence to this author at: Dr Ruth M Ayling, Department of Clinical Biochemistry, Derriford Hospital, Plymouth PL6 8DH, UK, Fax: 01752 792400; e-mail ruthayling@clinicalbiochemistry.org.uk

The first 20% of the full text of this article appears below.


To the Editor:

Tazocin is an injectable antibiotic preparation with broad-spectrum activity against aerobic and anaerobic gram-positive and gram-negative bacteria (1). Reported side effects that might prompt metabolic disease investigations include change in consciousness and encephalopathy (2)(3). We report 2 patients in whom interpretation of organic acid analysis was complicated by administration of tazocin.

Case 1 was a 56-year-old man admitted for routine aortobifemoral bypass graft surgery. Past medical history included peripheral vascular disease, hypercholesterolemia, and epilepsy. Postoperatively the patient developed an acute abdomen and at laparotomy required extensive small bowel resection to . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.